Docmode Health Technologies logo

Docmode Health Technologies financials: balance sheet, profit and loss, cash flow

NSE: DHTLOther Consumer Services

Docmode Health Technologies Limited · Face value ₹10 · Listed Feb 2024 · Issue price ₹79
Last close ₹22.05up ₹0.05 (0.23%)

Share price at the NSE close on 27 Oct 2026. Previous close ₹22.00.

27 Oct: open ₹21.90, high ₹22.05, low ₹21.90

52-week range of traded prices to 27 Oct 2026
₹21.90Low, 27 Oct 2026₹125.20High, 3 Nov 2025
Market cap
₹6.93 Cr
P/E
Lossover the last 12 months
P/B
0.84
Dividend yield
Nonein the last 12 months
ROE
−1.9%
Debt to equity
0.45
Volume, NSE
1,600100.0% delivered

Docmode Health Technologies' financial statements for the 3 years to Mar 2026, consolidated: the company and its subsidiaries together.

3 years at a glance

₹ crore, years to March.Docmode Health Technologies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
400.2Mar 2442−2.06.8Mar 2526−0.13.7Mar 26
Peak revenue ₹42 Cr, year to Mar 2025; lowest ₹26 Cr, year to Mar 2026A loss in 2 of the 3 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
4.7%−4.9%4.7%−1.6%−1.3%0.5%−4.9%−0.6%Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue26
  2. Materials and goods−20
  3. Employee costs−2.7
  4. Other expenses−3.2
  5. Operating profit−0.3
  6. Depreciation−0.2
  7. Other income+1.4
  8. Finance costs−1.0
  9. Profit before tax−0.1
  10. Tax0.0
  11. Net profit−0.1

What the company owns

  • Plant, investments and other assets₹18 Cr
  • Inventory₹8 Cr
  • Receivables₹7 Cr
  • Cash and bank₹0 Cr
  • Current investments₹0 Cr

What pays for it: net worth and liabilities

  • Other liabilities₹18 Cr
  • Net worth₹8 Cr
  • Borrowings₹4 Cr
  • Owed to suppliers₹4 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Docmode Health Technologies half-yearly results

₹ croreMar 2024Mar 2025Mar 2026Filed 4 Sep
Revenue from operations40.041.825.5
38.142.425.9
Materials and goods bought0.036.119.9
Employee costs5.03.82.7
Other expenses33.22.63.2
Operating profit before depreciation1.9−0.7−0.3
Operating margin4.7%−1.6%−1.3%
Materials, % of revenue0.0%86.5%78.0%
Employee costs, % of revenue12.4%9.0%10.7%
Other expenses, % of revenue82.9%6.2%12.7%
Depreciation and amortisation0.00.30.2
Operating profit after depreciation1.9−1.0−0.6
Other income0.10.91.4
Finance costs1.71.91.0
One-off items0.0––
Profit before tax0.3−2.0−0.1
0.20.10.0
Net profit0.2−2.0−0.1
Net margin0.5%−4.9%−0.6%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Mar 2026Filed 4 Sep
8.38.2
8.38.2
Share capital3.13.1
Reserves5.25.1
Belonging to outside owners of subsidiaries0.00.0
6.83.7
29.123.6
1.81.7
Total assets39.333.5
14.416.3
24.917.2
Net debt4.93.5
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Mar 2026Filed 4 Sep
6.74.3
6.83.7
7.02.8
Receivables2.21.8
Inventories−8.73.4
Payables2.6−1.8
Other working capital10.8−0.6
Tax paid−0.10.0
Capital spending0.00.0
Free cash flow6.74.3
−3.7−1.9
−4.3−4.1
Dividends paid0.00.0
Shares issued0.00.0
Net change in cash−1.3−1.7
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2024.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2024Mar 2025Mar 2026Filed 4 Sep
Earnings per share–−₹6.45−₹0.43
Diluted earnings per share–−₹6.45−₹0.43
Book value per share–₹26.56₹26.14
Shareholder yield–0.0%0.0%
Market cap at the year end (₹ crore)67.215.612.7

Ratios

Consolidated, years to March.Docmode Health Technologies PE ratio and valuation

RatioMar 2024Mar 2025Mar 2026Filed 4 Sep
Revenue growth–4.4%−38.9%
–−24.3%−1.7%
––22.6 pts
From the net margin––21.5 pts
From asset turnover––0.9 pts
From borrowing––0.1 pts
Return on capital employed–−6.4%−4.8%
Interest cover1.1––
Debt to equity–0.820.45
Receivable days–81106
Inventory days–113142
Payable days–5464
Cash conversion cycle, days–140184
Working capital days–−4−58
Asset turnover–1.060.70
Assets per rupee of net worth–4.714.40
Sales per rupee of plant–34.6026.12
Capital spending to depreciation–0.000.00
Interest cover is left blank for the years to Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−0.4%
Measure3 years
Return on equity, average−13.0%
Return on capital employed, average−5.6%
Operating margin, average0.6%
Net margin, average−1.6%
Asset turnover, average0.88
Cash conversion cycle, days, average162
Debt to equity, average0.64

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations4.30
Cash from investing−1.89
Cash from financing−4.06
Capital spending0.00
Dividends paid0.00
Shares issued for cash0.00
Borrowings repaid0.04